SBIR/STTR Research Award
Manufacturing of Growth Factors to Enable Cardiopoietic Stem Cell Therapy for Hea
Award amount
$224,139Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- APT THERAPEUTICS, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- U14VGSZ1X7H8
- Solicitation number
- PA13-234
- Topic code
- NHLBI
Research abstract
DESCRIPTION (provided by applicant): Cardiopoietic cell therapy significantly improved left ventricular function, blunted pathological remodeling, and functional outcomes in animal models and Phase I/II clinical trial of heart failure patients. There is ongoing Phase III trial. In this therapeutic approach, bone marrow-derived mesenchymal stem cells are engaged into cardiac stem cells by exposing to a cardiogenic cocktail of growth factors, including activin A, transforming growth factor-b1, and bone morphogenetic protein-4, which is the single largest cost component of clinical manufacturing. These cytokines all belong to the TGF-b superfamily, which are critical for cardiopoietic stem cell expansion and differentiation. However, due to the complex post-proteolytic modifications and poor solubility at neutral pH, yield from all the curren manufacturing process is very low, and as a result bulk volume is uneconomical and not readily available. Currently, commercial products are transiently produced in no
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Multi-functional anti-thrombotic therapy for coronary microvascular obstruction
- Immunomodulatory Therapy for Neuropathic Pain
- Peripherally Acting Analgesic for Osteoarthritis Pain
- Anti-inflammatory and Anti-diabetic Therapy for Metabolic Syndrome
- Combination treatment with tPA and IL2 analog for Stroke
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY
- Head Up CPR and Aortic Occlusion to Improve Survival after Refractory Cardiac Arrest
- Free-Breathing Dynamic Cardiopulmonary Function Imaging System to use with Xenon MRI
- The Next Wave of Asthma Therapeutics
- Bearingless flux reversal motor for neonatal and pediatric extracorporeal life support applications
Research funding history
32 SBIR/STTR records share this UEI (2004–2023). Reported award amounts total $22,373,259. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services